Multicenter prospective observational study to identify plasm beta cell-specific peptides
Not Applicable
Recruiting
- Conditions
- Type 1 diabetes
- Registration Number
- JPRN-jRCT1030220111
- Lead Sponsor
- Miyatsuka Takeshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
More than 18 years old patients with a diagnosis of type 1 diabetes and type 1 diabetes caused by immune checkpoint inhibitors from the date of approval by the hospital director to March 31, 2025, have been started treatment at the Department of Endocrinology and Metabolism, Kitasato University Hospital or the Department of Endocrinology and Metabolism, Kitasato University Medical Center, understand the purpose of this study and are given consent. More than 18 years old normal glucose-tolerant subjects (volunteers) understand the purpose of the study and are given their consent. Volunteers will be recruited by posting posters on the bulletin board in the School of Medicine.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of plasma peptides specific to patients with type 1 diabetes and patients with type 1 diabetes induced by immune checkpoint inhibitors.
- Secondary Outcome Measures
Name Time Method Comparison of plasma peptides at study entry and 12-24 weeks after entry in patients with type 1 diabetes and type 1 diabetes induced by immune checkpoint inhibitors.